Diabetic Foot Osteomyelitis Caused by Co-Infection with Methicillin-Resistant Staphylococcus aureus and Multidrug-Resistant Extended-Spectrum ß-Lactamase-Producing Escherichia coli: A Case Report

• Published in: Applied Microbiology (Basel) Vol. 3; no. 3; pp. 1046 - 1056
• Main Authors: Kitaya, Shiori, Miura, Chieko, Suzuki, Ayano, Imai, Yoshimichi, Tokuda, Koichi, Kanamori, Hajime
• Format: Journal Article
• Language: English
• Published: MDPI AG 07.09.2023
• Subjects: diabetic foot infections; diabetic foot osteomyelitis; methicillin-resistant Staphylococcus aureus; multidrug-resistant extended-spectrum ß-lactamase-producing Escherichia coli
• ISSN: 2673-8007; 2673-8007
• DOI: 10.3390/applmicrobiol3030072

This case report describes a 47-year-old man with type 2 diabetes and its associated complications. The patient developed co-infection with methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant (MDR) extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli following surgical amputation for osteomyelitis caused by diabetic foot infection (DFI). The patient had a history of recurrent hospitalization due to DFI and had received multiple antimicrobials. Intraoperative wound cultures identified MRSA and MDR ESBL-producing E. coli as the causative agents of the co-infection. Intravenous vancomycin and meropenem were administered. After surgery, daily debridement and hyperbaric oxygen therapy were performed. The patient underwent surgical wound closure and was discharged on day 86. Polymicrobial infections in DFIs worsen antimicrobial resistance, impede wound healing, and increase the risk of osteomyelitis and amputation. Furthermore, infections caused by MDR bacteria exacerbate challenges in infection control, clinical treatment, and patient outcomes. In DFI cases caused by co-infection with MDR bacteria, prompt and appropriate antimicrobial therapy, debridement, and regular wound care while considering transmission are essential.